Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer (Q39550421)

13 September 2017

Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer (English)

1 reference

13 September 2017

1 reference

9

1 reference

13 September 2017

M Musumeci

1

1 reference

13 September 2017

V Coppola

2

1 reference

13 September 2017

A Addario

3

1 reference

13 September 2017

M Patrizii

4

1 reference

13 September 2017

M Maugeri-Saccà

5

1 reference

13 September 2017

L Memeo

6

1 reference

13 September 2017

C Colarossi

7

1 reference

13 September 2017

F Francescangeli

8

1 reference

13 September 2017

D Collura

10

1 reference

13 September 2017

A Giacobbe

11

1 reference

13 September 2017

L D'Urso

12

1 reference

13 September 2017

M Falchi

13

1 reference

13 September 2017

M A Venneri

14

1 reference

13 September 2017

G Muto

15

1 reference

13 September 2017

R De Maria

16

1 reference

13 September 2017

D Bonci

17

1 reference

13 September 2017

language of work or name

English

0 references

publication date

2 May 2011

1 reference

13 September 2017

1 reference

13 September 2017

30

1 reference

13 September 2017

41

1 reference

13 September 2017

4231-4242

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2011.140

13 September 2017

0 references

cites work

Paths of FGFR-driven tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

miR-15a and miR-16-1 in cancer: discovery, function and future perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

MicroRNAs: genomics, biogenesis, mechanism, and function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Stromal fibroblasts in cancer initiation and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

MicroRNA-cancer connection: the beginning of a new tale

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Stromal-epithelial interactions: II. Regulation of prostatic growth by embryonic urogenital sinus mesenchyme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

miR-15 and miR-16 induce apoptosis by targeting BCL2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Inflammation in prostate carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

A new therapy paradigm for prostate cancer founded on clinical observations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Tumor-stroma co-evolution in prostate cancer progression and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Microenvironmental regulation of metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

The basics of epithelial-mesenchymal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

The VEGF IRESes are differentially susceptible to translation inhibition by miR-16

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

The role of fibroblast growth factors and their receptors in prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Prediction of mammalian microRNA targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Minireview: regulation of prostatic stem cells by stromal niche in health and disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

NF-κB targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Inhibition of export of fibroblast growth factor-2 (FGF-2) from the prostate cancer cell lines PC3 and DU145 by Anvirzel and its cardiac glycoside component, oleandrin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Epithelial-mesenchymal transitions in tumour progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Epithelial-mesenchymal transitions in development and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Tumor-stroma interactions of metastatic prostate cancer cell lines: analyses using microarrays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.140

31 March 2020

Identifiers

DOI

10.1038/ONC.2011.140

1 reference

Dimensions Publication ID

13 September 2017

0 references

1 reference